[HTML][HTML] The role of biosimilars in uveitis: long-term real-world outcomes of the switch from original to biosimilar TNF-alpha inhibitors
Background: Recent expiry of patents for tumor necrosis factor (TNF)-α inhibitors has led to
the employment of biosimilars in clinical practice. The aim of the study was to identify any …
the employment of biosimilars in clinical practice. The aim of the study was to identify any …
Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Behcet's uveitis with vasculitis
S Yang, Z Huang, X Liu, H Li, L Xie, X Chen… - International …, 2021 - Elsevier
Background Anti-tumor necrosis factor-alpha was regarded as an option in treatment of non-
infectious uveitis. However, few studies in the far easter region have concentrated on this …
infectious uveitis. However, few studies in the far easter region have concentrated on this …
Characteristics of patients with Behcet disease from the Van Province, Eastern Turkey: definition of disease clusters in a Tertiary Referral Center
E Oguz, M Bektaş - JCR: Journal of Clinical Rheumatology, 2023 - journals.lww.com
Background Behçet disease (BD) is a chronic inflammatory systemic disease that affects
skin mucosa, joints, eyes, and blood vessels. Behçet disease shows some clinical …
skin mucosa, joints, eyes, and blood vessels. Behçet disease shows some clinical …
[HTML][HTML] Anti-tumour necrosis factor-alpha agent therapy, compared with conventional therapy, reduces the relapse of uveitis in patients with behçet's disease: A …
X Zhou, X Shi, Y Ren, T Yan, Q Ye - Frontiers in Pharmacology, 2022 - frontiersin.org
Purpose: Anti-tumour necrosis factor-alpha (TNF-α) agents are often used for Behçet's
disease (BD) in clinical practice, but they have not been validated by a high level of …
disease (BD) in clinical practice, but they have not been validated by a high level of …
[HTML][HTML] Behcet disease
A Adil, A Goyal, JM Quint - 2017 - europepmc.org
Objectives: Describe the pathophysiology of Behcet disease. Review the presentation of a
patient with Behcet disease. Outline the management options available for Behcet disease …
patient with Behcet disease. Outline the management options available for Behcet disease …
Current knowledge of biologics in treatment of noninfectious uveitis
S Gupta, K Shyamsundar, M Agrawal… - Journal of Ocular …, 2022 - liebertpub.com
The arena of uveitis deals with a number of entities, which can be infectious or immune
mediated. Noninfectious uveitis (NIU) has been managed with corticosteroids and …
mediated. Noninfectious uveitis (NIU) has been managed with corticosteroids and …
Management of Behçet's disease
F Alibaz-Oner, AH Sawalha… - Current Opinion in …, 2018 - journals.lww.com
Prospective and controlled studies for the management of major organ involvement in
Behçet's disease are still limited. Data from primarily retrospective studies confirmed better …
Behçet's disease are still limited. Data from primarily retrospective studies confirmed better …
Behçet's disease uveitis: is there a need for new emerging drugs?
I Tugal-Tutkun, P Çakar Özdal - Expert Opinion on Emerging Drugs, 2020 - Taylor & Francis
Introduction: Behçet's disease uveitis (BDU) is a potentially blinding disorder. Systemic
treatment with disease-modifying anti-rheumatic drugs (DMARDs) is mandatory in patients …
treatment with disease-modifying anti-rheumatic drugs (DMARDs) is mandatory in patients …
Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab
To identify clinical variables capable of predicting long-term treatment duration of TNF-α
inhibition in patients with Behçet's disease (BD)-related uveitis. Demographic, clinical, and …
inhibition in patients with Behçet's disease (BD)-related uveitis. Demographic, clinical, and …
Ultra-widefield fluorescein angiography to monitor therapeutic response to adalimumab in Behcet's uveitis
Purpose To investigate the role of ultra-widefield fluorescein angiography (UWFA) for
monitoring therapeutic response to adalimumab in patients with Behcet's uveitis. Methods …
monitoring therapeutic response to adalimumab in patients with Behcet's uveitis. Methods …